583 related articles for article (PubMed ID: 33596848)
21. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
[TBL] [Abstract][Full Text] [Related]
22. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
[TBL] [Abstract][Full Text] [Related]
23. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
[TBL] [Abstract][Full Text] [Related]
24. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
[No Abstract] [Full Text] [Related]
25. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
Trials; 2020 May; 21(1):383. PubMed ID: 32370774
[TBL] [Abstract][Full Text] [Related]
26. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
27. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis.
Zheng X; Ning Z; Drobniewski F; Yang J; Li Q; Zhang Z; Hu Y
Int J Antimicrob Agents; 2017 Feb; 49(2):183-188. PubMed ID: 28012685
[TBL] [Abstract][Full Text] [Related]
28. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
29. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
30. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
31. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.
Pierre-Audigier C; Surcouf C; Cadet-Daniel V; Namouchi A; Heng S; Murray A; Guillard B; Gicquel B
Int J Tuberc Lung Dis; 2012 Feb; 16(2):221-3, i-ii. PubMed ID: 22236923
[TBL] [Abstract][Full Text] [Related]
32. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
Sun F; Li Y; Chen Y; Guan W; Jiang X; Wang X; Ren P; Li J; Shi J; He G; Wu M; Tang P; Wang F; Sheng Y; Huang F; Zhou Z; Huang H; Hong L; Liu Q; Zhang Y; Zhang W
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578402
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
Che Y; Bo D; Lin X; Chen T; He T; Lin Y
BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
[TBL] [Abstract][Full Text] [Related]
34. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
35. Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania.
Katale BZ; Mbelele PM; Lema NA; Campino S; Mshana SE; Rweyemamu MM; Phelan JE; Keyyu JD; Majigo M; Mbugi EV; Dockrell HM; Clark TG; Matee MI; Mpagama S
BMC Genomics; 2020 Feb; 21(1):174. PubMed ID: 32085703
[TBL] [Abstract][Full Text] [Related]
36. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
[TBL] [Abstract][Full Text] [Related]
38. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
Dhingra VK; Rajpal S; Mittal A; Hanif M
Indian J Tuberc; 2008 Jan; 55(1):15-21. PubMed ID: 18361306
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
[TBL] [Abstract][Full Text] [Related]
40. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Forsman LD; Jonsson J; Wagrell C; Werngren J; Mansjö M; Wijkander M; Groenheit R; Hammar U; Giske CG; Schön T; Bruchfeld J
Clin Infect Dis; 2019 Sep; 69(8):1394-1402. PubMed ID: 30561569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
